title: Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
authors.affiliation: Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, 15 Marmara St, Thessaloniki, 551 32, Greece.. vathyros@gmail.com.
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.forename: Asterios
authors.initials: A
authors.lastname: Karagiannis
mesh_terms: D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide / Q000627:therapeutic use; D065626:Non-alcoholic Fatty Liver Disease / Q000097:blood / Q000188:drug therapy*; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1